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EV-C/D and FP open, these were 41% and 32% for reinterventions and 20%
and 17% for a new bypass, respectively. The overall amputation rate was 1.2%.
Conclusions: Clinical benefit for DC is excellent in AI, irrespective of
TASC, and in FP segment with TASC A/B. Acceptable durability in FP
TASC C/D can be achieved, however reinterventions are frequently needed,
irrespective of type of revascularization.
Table. Primary (PP), secondary patency (SP), sustained clinical success
(SusClSuc) and secondary clinicals
Variable
PP SP SusClSuc SecClSuc
24 mo 48 mo 24 mo 48 mo 24 mo 48 mo 24 mo 48 mo
(%) (%) (%) (%) (%) (%) (%) (%)
AI open
(n  47)
91  4 91  4 94  4 94  4 91  4 91  4 96  3 96  3
AI A/B
(n  91)
94  3 87  4 98  2 98  2 90  3 75  5 98  2 98  2
AI C/D
(n  35)
100 100 100 100 100 100 100 100
P .425 .206 .118 .429
FP open
(n  60)
64  6 54  7 75  6 71  6 64  6 54  7 86  5 80  6
FP A/B
(n  29)
93  5 83  8 97  3 97  3 93  5 83  8 100 100
FP C/D
(n 51)
46  7 46  7 68  7 63  7 46  7 46  7 82  6 82  6
P .001 .005 .002 .043
A Comparison of Rigid vs Soft Dressings in the Healing of Below Knee
Amputations (BKA)
Sarah Shine, Brandon J. Sumpio, David Mahler, Bauer E. Sumpio. Yale
University School of Medicine, New Haven, Conn
Introduction and objectives: There is no standard protocol for the
selection of surgical dressings after a below knee amputation (BKA). The
purpose of this study was to compare rigid dressings with soft dressings on
the healing times of BKA. We hypothesized that rigid dressings would
facilitate faster wound healing and residual limb maturation by minimizing
postsurgical edema and pain, preventing knee flexion contracture, and
protecting the residual limb from trauma.
Methods: Our retrospective analysis compared 151 patients who un-
derwent BKA from 2000 to 2012 at Yale New Haven Hospital, after which
60 patients received soft dressings and knee immobilizers (soft) after the
amputation, and 92 were placed in a rigid plastic or plaster prosthesis (rigid).
Demographics and outcomes, including time between amputation and
initial casting of prosthesis, were compared.
Results: Age and diabetic status was not statistically different between
the soft (61.0 years, 82.8% with diabetes) and rigid groups (58.6 years,
78.0% with diabetes). After BKA, the rigid dressing group demonstrated
significantly decreased time spans from amputation to initial casting, as
shown by the Fig (P  .02 by log-rank and Wilcoxon test) and the Table.
After 60 days, 58.24% of the rigid group was cast, compared with 38.33% of
soft group (P  .03 by t test).
Conclusions: Use of a rigid dressing after a BKA significantly short-
ened the time to healing, as assessed by the time to casting. Use of a rigid
prosthesis allows for consistent dressing changes of the healing BKA stump
while facilitating inspection of the limb.
Table. Days to casting
Type of dressing Median Mean
Percentile
25th 75th
Rigid 43 76 30 102
Soft 75 127 41 127
Open Surgical Revision of Unfavorable Vein Graft Lesions Provides a
More Durable Repair
Rodney P. Bensley, Jr, Michelle C. Martin, Jeremy D. Darling, Ruby C. Lo,
Margriet Fokkema, Mark C. Wyers, Allen D. Hamdan, Marc L. Schermer-
horn. Beth Israel Deaconess Medical Center, Boston, Mass
Introduction and objectives: Prior studies have demonstrated that
favorable vein graft lesions (single, 2-cm lesions in grafts older than 3
months) can be treated successfully with percutaneous transluminal angio-
plasty (PTA) and other endovascular techniques. However, the optimum
treatment method for unfavorable lesions is not yet clear.
Methods: This was a retrospective review (2000-2011) of patients
undergoing PTA or open revision of failing infrainguinal vein grafts. Demo-
graphics, comorbidities, lesion characteristics, and procedural information
were recorded. Failure was defined as restenosis by duplex scan, occlusion,
redo PTA, surgical revision, or amputation. Cox proportional hazard models
and life-table analyses were performed. We report 12-month failure rates.
Results: We studied 176 failing vein grafts in 169 patients: 84 grafts
underwent PTA and 92 open revision. Mean age was similar between PTA
and open revision (67.5 vs 69.5 years, P  .28) as was the proportion with
asymptomatic failing grafts (54.7% vs 52.1%, P  .76). Grafts undergoing
PTA were more likely to be unfavorable (64.3% vs 45.7%, P  .01) with
multiple lesions (32.1% vs 14.1%, P  .01) and lesions 2 cm (44.0% vs
21.7%, P  .01). Overall, PTA failed more than open revision (65.4% vs
44.5%, P .01). Freedom from PTA failure was greater in favorable lesions
compared with unfavorable (52.3% vs 30.5%, P  .01). Favorability had no
influence on freedom from open revision failure (65.7% vs 70.5%, P .072).
Among favorable lesions, there was no difference in freedom from failure
between PTA and open revision (52.3% vs 65.7%, P  .68). However,
unfavorable lesions fared much worse after PTA (30.5% vs 70.5%, P  .01;
Fig). There were no predictors of open revision failure. Unfavorable lesions
(HR, 2.17 [1.16-4.00]; P .01) predicted PTA failure, primarily driven by
bypass graft age  3 months (HR, 2.84 [1.36-5.93]; P  .01).
Conclusions: Open revision of unfavorable vein graft lesions provides
greater freedom from failure and should be the primary therapy for failing
vein grafts with unfavorable lesions. Favorable vein grafts should continue to
be treated endovascularly.
Thirty-Day Readmission Following Lower Extremity Bypass for Crit-
ical Limb Ischemia (CLI) in the PREVENT III Cohort
James T. McPhee,1 Louis L. Nguyen,1 Karen J. Ho,1 Charles K. Ozaki,1
Michael S. Conte,2 Michael Belkin1. 1Brigham and Women’s Hospital,
Boston, Mass; 2University of California San Francisco, San Francisco, Calif
Introduction and objectives: Hospital readmission after lower ex-
tremity bypass (LEB) is an economic burden and a focal point for policyFig.
Fig.
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change directed at disease-specific bundling strategies. This study was per-
formed to evaluate rates and predictors of 30-day readmission from a
multicenter trial data set.
Methods: We analyzed the PREVENT III data set of 1404 CLI
patients undergoing LEB at 83 North American centers. The primary end
point was readmission 30 days of discharge. Secondary end points in-
cluded graft patency and limb salvage evaluated in the context of readmis-
sion.
Results: We analyzed 1356 patients, of these, 23 (1.7%) died in-
hospital and were excluded from re-admission analyses. Overall, 327 of 1333
patients (24.5%) were readmitted 30 days of discharge. Reasons for
readmission included 127 (39%) wound infections in the index leg, 75 (23%)
nonvascular reasons, 68 (20.9%) additional procedures in the index leg, and
19 graft failures (5.8%). Univariate predictors are shown in the Table.
Adjusted independent predictors of 30-day readmission included wound
infection (odds ratio [OR], 4.1; 95% confidence interval [CI], 3.0-5.4; P
.0001), renal failure (OR, 4.1; 95% CI, 1.9-8.8; P  .0004), early lost
patency (OR, 1.9; 95% CI, 1.2-2.9; P  .003), dialysis (OR, 1.8; 95% CI,
1.2-2.6; P .003), and female gender (OR, 1.3; 95% CI, 1.0-1.8; P .03).
Patients readmitted 30 days had lower rates of limb salvage at 1 year
(78%  2.4% vs 91%  0.9%, P  .0001). Thirty-day readmission was
predictive of limb loss (HR, 2.25; 95% CI, 1.6-3.1; P  .0001) at 1 year,
after adjustment for other factors.
Conclusions: Readmission after LEB for CLI is common (24%) and
associated with defined clinical predictors. Readmission is associated with
long-term limb loss. These data provide benchmark values for this complex
patient population and may prove useful as disease-specific bundling strate-
gies are derived.
Table. Univariate predictors of 30-day readmission after vein graft bypass
for CLI
Factors
30-day readmission
PNo Yes
Pre-op factors, No. (%)
Female gender 333 (33.1) 142 (43.4) .0008
Dialysis dependence 109 (10.9) 52 (15.9) .02
Tissue loss indication 733 (72.9) 255 (78.0) .05
Post-op factors
Length of stay, mean
[SD] days
8.4 [8.9] 9.7 [9.1] .0009
Wound infection,
No. (%)
140 (13.9) 133 (40.7) .0001
Acute renal failure,
No. (%)
15 (1.5) 17 (5.2) .0005
Early graft-related
event, No. (%)
76 (7.5) 44 (13.5) .002
The Endurant Stent-Graft U.S. Clinical Trial: 2-Year AAA Diameter
Outcomes Are Predicted by 6-Month Volume Outcomes
Emily Spangler,1 Mark Fillinger,1 Ronald M. Fairman,2 Matthew J. Eagle-
ton,3 Manish Mehta,4 Paul Anain,5 Michel Makaroun6. 1Dartmouth
Hitchcock Medical Center, Lebanon, NH; 2Hospital of the University of
Pennsylvania, Philadelphia, Pa; 3The Cleveland Clinic Foundation, Cleve-
land, Ohio; 4Albany Medical Center Hospital, Albany, NY; 5Vascular and
Endovascular Center of WNY, Buffalo, NY; 6Universtiy of Pittsburgh Med-
ical Center, Pittsburgh, Pa
Introduction and objectives: This study reports the 2-year diameter
and volume data for abdominal aortic aneurysms (AAAs) treated in the U.S.
pivotal clinical trial of the Endurant Stent Graft System.
Methods: From April 2008 to May 2009, 150 patients were treated
with the Endurant stent graft as part of a prospective multicenter trial. The
main inclusion criteria were AAA diameter 5 cm, neck length 10 mm,
and neck angulation 60°. A core laboratory reviewed all imaging. Expan-
sion was defined as 5 mm diameter or 5% by 3-dimenional volume.
Results: Stent graft implant was successful in 149 of 150 patients. The
6-month volume results were nearly identical to the 24-month diameter
results, and all AAAs identified with expansion by diameter at 24 months had
expansion by volume criteria (but not diameter) at 6 and 12 months.
Change in AAA size was more likely to be identified by volume at all time
points, with13% of AAAs classified as “no change” by volume criteria at 1
and 2 years (P  .05). Most AAAs classified as “no change” by diameter
criteria were shrinking by volume criteria. Secondary intervention for en-
doleak occurred in five patients, all suspected type II endoleak. All were
identified as expanding earlier by volume, including two ultimately identi-
fied to be a type I endoleak. There were no ruptures or aneurysm-related
deaths.
Conclusions: Midterm results of the Endurant pivotal trial are good,
with low expansion rates at 2 years, even by volume criteria. Three-
dimensional volume detects aneurysm shrinkage and expansion on average
18 months sooner than diameter, allowing for earlier reassurance in most
patients and earlier intervention in the small minority who need it.
Table. AAA outcomes over time
Outcome Decrease (%) No change (%) Increase (%)
Diameter
6 mon 31 69 0
12 mon 47 53 0
24 mon 63 35 2
Volume
6 mon 63 34 4
12 mon 79 13 7
24 mon 78 12 10
The Effect of Chronic Oral Anticoagulation on the Durability and
Success of Endovascular Aortic Aneurysm Repair (EVAR)
Marques Johnson, Jasmine Chiang, Jens Eldrup-Jorgensen, Clark David,
Christopher T. Healey. Maine Medical Center, Portland, Me
Introduction and objectives: It has been suggested that long-term
use of warfarin can affect the durability of endovascular aneurysm repair
(EVAR) by continued sac expansion, possible rupture, and the need for
further surgical interventions. The purpose of this study was to determine
whether chronic anticoagulation therapy with warfarin is associated with an
increased risk of rupture or need for reintervention after EVAR.
Methods: We reviewed the records of 401 consecutive patients who
underwent EVAR at a single institution from 2003 until 2011. Patients on
warfarin were compared with a control group not anticoagulated. Primary
end points were rupture, explant, reintervention, death, and a composite
outcome if any of these occurred. The presence of an endoleak at last
follow-up and change in aneurysm sac size of 5 mm were secondary end
points. Cox proportional hazards models were used to estimate the effect of
warfarin use on the primary and secondary outcomes, controlling for age,
sex, obesity, specific comorbidities, antiplatelet drugs, statin use, and ur-
gency of EVAR.
Results:Of 401 patients, 363 (90.5 %) with a median follow-up period
of 29 months had sufficient data for analysis. Warfarin use was not associated
with an increased risk of any of the primary or secondary end points (Table).
After controlling for covariates and length of observation via Cox propor-
tional hazards models, we found the effect of warfarin remained insignifi-
cant. There was an increased in endoleak rate and adverse outcomes after
emergency EVAR and in those patients deemed unfit for open surgical
repair.
Conclusions: Chronic oral anticoagulation with warfarin does not
appear to affect the incidence of endoleak after EVAR or the need for
reintervention. Adverse long-term results are more likely after emergency
EVAR.
Table.
Variable No.
Death, Explant, Reintervention, Any of these,
No. (%) No. (%) No. (%) No. (%)
Warfarin 68 7 (10) 3 (4) 6 (9) 16 (24)
No warfarin 295 35 (12) 5 (2) 25 (8.5) 65 (22)
P NS NS NS NS
Atrio-Femoral BypassWithMotor-Evoked Potential Monitoring Low-
ers the Rate of Death and Paraplegia After Complex Thoracoabdomi-
nal Aortic Aneurysm Repair
Robert T. Lancaster, Mark F. Conrad, Virendra I. Patel, Matthew R.
Cambria, Emel A. Ergul, Richard P. Cambria. Massachusetts General
Hospital, Boston, Mass
Introduction and objectives: We recently reported improved early
mortality and paraplegia rates in a small cohort of patients with type I-III
thoracoabdominal aortic aneurysms (TAA) treated with atrio-femoral by-
pass (AFB) and motor-evoked potentials (MEVP) when compared with a
propensity-matched cohort of patients treated with the clamp-and-sew
method (CS). The use of AFB/MEVP increases the level of complexity of
TAA repair, and it is unclear if the early benefits will be sustained when this
is applied to a general population with type I-III TAA, which is the goal of
this study.
Methods: Consecutive patients undergoing repair of nonruptured
Crawford extent I-III TAA from January 1987 to December 2011 were
identified. Patients were stratified according to operative approach (AFB/
MEVP vs CS). End points included long-term survival and the composite
outcome of perioperative death and paraplegia. A multivariate, risk-adjusted
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